All In Biotech

Drug Trial Radar · NCT03708900

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 28, 2021

Primary completion

Jul 21, 2027

Study completion Jul 21, 2027

Sponsor

Lead sponsor
RECORDATI GROUPIndustry
Sponsor type
Industry
First posted
Oct 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.

Conditions

  • Cushing Syndrome

Interventions

  • LCI699Drug

    osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's SyndromeTime frame: up to Week 12

Locations

15 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California San Francisco UCSF

    San Francisco, California · Recruiting

  • ABMED Clinical Research Corp

    Cape Coral, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois · Recruiting

  • National Institute of Child Health and Human Development

    Bethesda, Maryland · Completed

  • Texas Valley Clinical Research

    Weslaco, Texas · Recruiting

  • UZ Brussel

    Jette, Brussels Capital, Belgium · Completed

  • Multiprofile Hospital for Active Treatment Sveta Marina EAD

    Varna, Bulgaria · Withdrawn

  • Hospital Necker Enfants Malades

    Paris, France · Completed

  • Robert Debre Hospital

    Paris, France · Completed

  • CHU Bicetre APHP Paris Saclay

    Paris, France · Completed

  • Ospedale Bambino Gesu

    Roma, Italy · Completed

  • Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello

    Pisa, PI, Italy · Completed

  • University Clinical Center Ljubljana

    Ljubljana, Slovenia · Withdrawn

  • Alder Hey Childrens NHS Foundation Trust

    Liverpool, United Kingdom · Withdrawn

  • The Royal London Childrens Hospital

    London, United Kingdom · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.